Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $967,461.30 in Stock

Posted by Stanley Muller on Oct 8th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Roberto Vieira sold 8,333 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $116.10, for a total value of $967,461.30. Following the completion of the transaction, the insider directly owned 3,946 shares in the company, valued at $458,130.60. This trade represents a 67.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Roberto Wandenkolk Vieira also recently made the following trade(s):

On Wednesday, September 16th, Roberto Vieira sold 296 shares of Corcept Therapeutics stock. The shares were sold at an average price of $100.82, for a total value of $29,842.72.
On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08.

Corcept Therapeutics Stock Performance

Shares of Corcept Therapeutics stock opened at $119.60 on Thursday. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $126.38. The company’s 50 day moving average price is $114.98 and its 200-day moving average price is $83.08. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of 284.77 and a beta of 0.40.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm’s revenue was up 31.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.29 EPS. As a group, equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on CORT. Truist Financial started coverage on Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $164.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price on the stock. in a research note on Monday, July 27th. Finally, HC Wainwright restated a “buy” rating and set a $165.00 target price on shares of Corcept Therapeutics in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $138.17.

View Our Latest Stock Report on CORT

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CORT. QRG Capital Management Inc. raised its position in shares of Corcept Therapeutics by 25.4% in the 2nd quarter. QRG Capital Management Inc. now owns 9,042 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 1,834 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Corcept Therapeutics by 1.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 184 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at about $645,000. Tidal Investments LLC grew its position in Corcept Therapeutics by 9.2% during the 2nd quarter. Tidal Investments LLC now owns 24,218 shares of the biotechnology company’s stock valued at $2,106,000 after purchasing an additional 2,039 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new stake in Corcept Therapeutics during the 2nd quarter valued at about $558,000. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing medicines that modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol activity in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s principal commercial product is Korlym (mifepristone), a glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery.